CNTB Stock News & Analysis | Latest Updates

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

(NASDAQ:CNTB) SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually.

September 4, 2025Announcements

CNTB News

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

HC Wainwright & Co. Assumes Connect Biopharma Hldgs at Buy, Announces Price Target of $7

Connect Biopharma Files For Mixed Shelf Offering Of Up To $300M

Connect Biopharma Announces Reduction in Annualized Exacerbations With Rademikibart in Eosinophilic Driven, Type 2 Asthma Oral Presentations And Improvement In Lung Function with Rademikibart In Eosinophilic Driven, Type 2 Asthma In Two Oral Presentation

Connect Biopharma Presents Clinical And Preclinical Data Supporting Rademikibart At ATS 2025 International Conference

Connect Biopharma Hldgs Q1 EPS $(0.19) Down From $(0.16) YoY

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Following Written Agreement On Final Study Protocol From FDA; Expects To Report Topline Data In 1H 2026

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart For Acute Exacerbations In Asthma

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target

Connect Biopharma Reports Data From Global Phase 2 Trial Of Rademikibart In Patients With Moderate-To-Severe Uncontrolled Asthma

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target

Connect Biopharma FY24 EPS $(0.28) Up From $(1.13) YoY; Revenue $26M

Connect Biopharma Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma Presents Abstract About Results From Rademikibart Global Phase 2b Trial In Patients With Moderate-to-severe Asthma At ATS 2024 international Conference

Connect Biopharma Reports H1 2022 Cash, Cash Equivalents, And Short-term And Long-term Investments Were $212.9M

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

SVB Leerink Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $9

Connect Biopharma Announces Week 12 Top-Line Results From Phase 2 CBP-307 Trial In Patients With Moderate-To-Severe Ulcerative Colitis; Says 'intends to engage in partnership discussions for future development of CBP-307 to focus on lead program CBP-201'